

March 29, 2017

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma announces Changes in Executive Officers

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) today announced that the following changes in Executive Officers.

(1) New Executive Officer (effective April 24, 2017)

Patricia S. Andrews (currently Boston Biomedical Pharma, Inc.)

(2) Retiring Executive Officer (effective March 31, 2017)

Chiang J. Li (currently Executive Officer, Boston Biomedical, Inc., Head of Global Oncology for Sumitomo Dainippon Pharma Group)

Sumitomo Dainippon Pharma already announced the change of chief executive officer at its U.S. consolidated subsidiary Boston Biomedical, Inc. and establishment of Global Head of Oncology, effective April 24, 2017, on March 22, 2017.

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)